» Articles » PMID: 39447854

Coronary Microvascular Dysfunction Beyond the Spectrum of Chronic Coronary Syndromes

Abstract

The prevalence of coronary microvascular dysfunction (CMD) beyond the spectrum of chronic coronary syndromes (CCS) is non-negligible, pertaining to pathophysiological and therapeutical implications. Thanks to the availability of accurate and safe non-invasive technique, CMD can be identified as a key player in heart failure, cardiomyopathies, Takotsubo syndrome, aortic stenosis. While CMD is widely recognized as a cause of myocardial ischemia leading to a worse prognosis even in the absence of obstructive coronary artery disease, the characterization of CMD patterns beyond CCS might provide valuable insights on the underlying disease progression, being potentially a "red flag" of adverse cardiac remodeling and a major determinant of response to therapy and outcomes. In this review, we aimed to provide an overview of the latest evidence on the prevalence, mechanistic and prognostic implications of CMD beyond the spectrum of CCS (i.e. heart failure, cardiomyopathies, Takotsubo syndrome, aortic stenosis).

Citing Articles

Advances in the diagnosis and management of post-percutaneous coronary intervention coronary microvascular dysfunction: Insights into pathophysiology and metabolic risk interactions.

Tang N, Li K, Li H, Zhang Q, Hao J, Qi C World J Cardiol. 2025; 17(2):103950.

PMID: 40061275 PMC: 11886395. DOI: 10.4330/wjc.v17.i2.103950.


The Role of Circulating Biomarkers in Patients with Coronary Microvascular Disease.

Quarta R, Martino G, Romano L, Lopes G, Greco F, Spaccarotella C Biomolecules. 2025; 15(2).

PMID: 40001480 PMC: 11853534. DOI: 10.3390/biom15020177.